Healthcare Equipment and Supplies
Company Overview of Bactiguard AB
Bactiguard AB provides solutions for reducing device related hospital and care acquired infections. The company offers Bactiguard Infection Protection (BIP) central venous catheters that are used to administer drugs and intravenous solutions, and blood samples, as well as blood pressure monitoring; and BIP endotracheal tubes for use in airway management by oral or nasal intubation of the trachea. It also provides BIP Foley Catheter, a coated latex catheter that is used for drainage and irrigation of the bladder; and BIP Foley Catheter–Silicone, a silicone catheter for drainage and irrigation of the bladder. The company was founded in 2005 and is based in Stockholm, Sweden.
Stockholm, 114 35
Founded in 2005
Key Executives for Bactiguard AB
Chairman and Chief Executive Officer
Executive Vice President and Sales Manager
Compensation as of Fiscal Year 2017.
Bactiguard AB Key Developments
The Central Drugs Standard Control Organisation Announces the Regulatory Approval for Bactiguard's Central Venous Catheters in India
Aug 30 17
The Central Drugs Standard Control Organisation (CDSCO), under the Ministry of Health & Family Welfare, has announced the regulatory approval of Bactiguard's central venous catheters for infection prevention (BIP CVC). Bactiguard has earlier received product approval for its infection preventive urinary catheters (BIP Foley) and sales in India started in 2015. In parallel, a clinical study, involving 1,000 patients in total, at six prestigious hospitals in different regions of the country is being conducted. The regulatory approval for BIP CVC, a class III product with higher safety requirements than for BIP Foley, which is a class IIb product, is unconditional and there are no requirements for post approval clinical trials. Central venous catheters with antimicrobial coatings have gained increasing importance, given the escalating costs associated with hospital acquired infections, particularly in ICUs where patients are critically ill and CVCs are frequently used in their treatment.
Bactiguard Wins Tender for Urinary Catheters for Stockholm County Council
May 23 17
Bactiguard has won a tender for urinary catheters for the Stockholm county council, which enables healthcare providers in both primary and secondary
care to purchase Bactiguards' anti-infective urinary catheters. The contract is valid for 2 years and can be extended for another 2 years. The contract runs for two years from 6 November, 2017 and comprises BIP Foley Catheter in latex, BIP Foley Catheter Silicone and BIP Foley Tiemann.
Bactiguard AB Reports Earnings Results for the Third Quarter and Nine Months Ended of September 30, 2015
Nov 12 15
Bactiguard AB reported earnings results for the third quarter and nine months ended of September 30, 2015. For the quarter, the company’s revenues amounted to SEK 61.4 million against of SEK 28.1 million. The increase of 118 % compared to the corresponding quarter 2014 is mainly attributable to the additional order from C.R. Bard. EBITDA amounted to SEK 33.9 million against of SEK 2.2 million. Operating profit amounted to SEK 25.7 million compared to operating loss of SEK 5.3 million. Net profit amounted to SEK 6.1 million compared to net loss of SEK 15.7 million, corresponding to SEK 0.18 and SEK 0.47 per share. Operating cash flow for the quarter amounted to SEK 9.5 million compared to negative operating cash flow of SEK 21.8 million, corresponding to SEK 0.29 or SEK 0.66 per share.
For the nine months, the company’s revenues for the period amounted to SEK 118.0 million compared to SEK 93.8 million, an increase by 26 % compared to the corresponding nine-month period last year. The increase is mainly attributable to the additional order from C.R. Bard. Negative EBITDA for the period amounted to SEK 2.9 million compared to EBITDA of SEK 14.2 million. Adjusted for these items, EBITDA amounted to SEK 32.5 million. Operating loss amounted to SEK 27.4 million compared to SEK 8.2 million a year ago. Net loss for the period amounted to SEK 36.4 million compared to SEK0 79.4 million, corresponding to SEK 1.09 and SEK 3.17 per share. Negative operating cash flow amounted to SEK 6.9 million against of SEK 12.4 million, corresponding to SEK 0.21 and SEK 0.5 per share.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|